PGxAI
Contact for pricing
Overview
PGxAI is a configurable, clinician-facing clinical decision support platform designed to streamline precision medicine and pharmacogenomics. The software surfaces critical drug-drug interactions, contraindications, and personalized pharmacogenomic guidance derived from FDA-required labeling and established clinical guidelines for independent clinician review.
The platform is built for healthcare systems, diagnostic laboratories, and contract research organizations. It supports clinicians across various specialties—such as primary care, endocrinology, and cardiology—by helping them individualize drug therapies, including mainstream treatments like GLP-1 receptor agonists.
PGxAI integrates directly into existing electronic health record (EHR) and hospital workflows through native InterSystems IRIS for Health and FHIR standards, preventing workflow disruption. The platform ingests longitudinal patient data, laboratory information, and genetic profiles to deliver real-time, actionable insights at the point of care.
Notable Capabilities:
- Multi-Omics Intelligence: Integrates pharmacogenomic, proteomic, transcriptomic, and metabolomic biomarkers to predict drug efficacy, dosage requirements, and adverse-event risks.
- Broad Drug and Gene Coverage: Utilizes advanced models (such as Sirius) to analyze genetic variations across dozens of metabolic genes and hundreds of medications.
- Rapid Turnaround: Drastically reduces the time required to interpret complex genetic data from weeks to minutes.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Drug-drug interaction review
- Contraindication and precaution review
- Pharmacogenomic guidance retrieval
- Source-linked review support
- AI-powered multiomics platform
- Real-world evidence (RWE) integration
- Personalized drug selection and dosage optimization
- Integration with EHR and hospital workflows
- Rapid genetic data interpretation
- Multi-omics intelligence (proteomic, transcriptomic, metabolomic biomarkers)
Use Cases
- Personalizing GLP-1 drug treatment
- Reducing adverse drug reactions
- Optimizing drug development and clinical study design
- Tailoring chemotherapy and immunotherapy
- Guiding anticoagulation therapy
- Carrier screening and early disease detection
What Physicians Need to Know
Evidence Base
PGxAI surfaces pharmacogenomic guidance, drug-drug interactions, and contraindications from FDA-required labeling, CPIC guidelines, DPWG guidelines (where applicable), and FDA pharmacogenetic association resources. For specific 'bounded modules,' validated retrospective or real-world datasets may supplement these sources.
Clinical Validation Studies
PGxAI's AI-driven reports correlate patient genetic profiles with established pharmacogenomic markers and clinical evidence. A study evaluated an AI assistant using GPT-4 for interpreting PGx results, leveraging a knowledge base from CPIC, aiming to improve decision-making and patient care. Another study benchmarked large language models for replicating guideline-based PGx recommendations, with PGxAI's domain-adapted model achieving superior performance. PGxAI's platform has been shown to reduce turnaround time for genetic data interpretation to minutes.
Alert Fatigue Management
While specific details on PGxAI's alert fatigue management are not explicitly provided, the platform is designed to present evidence-linked clinical decision support in a structured workflow for licensed healthcare professionals. Effective clinical decision support tools are designed to provide actionable insights only when they change the clinical course, to avoid unnecessary noise and alert fatigue. Poorly designed active alerts can contribute to alert fatigue, and interruptive alerts are often used in PGx to communicate recommendations.
Override Rate Data
No specific override rate data for PGxAI is available. However, in general, computerized drug prescribing alerts can be overridden due to poor specificity and alert overload. A tiered approach with a selective knowledge base of clinically significant drug alerts and critical-high severity alerts being interruptive has achieved a 67% clinician acceptance rate in ambulatory computerized prescribing.
Drug Interaction Checking
PGxAI includes drug-drug interaction review, retrieving and displaying relevant findings from FDA-required labeling for the active medication list. The platform also identifies contraindications and precautions. The 'PGxAI Andromeda' app, an educational reference tool, helps users explore medication interactions and genetics-related information in publicly available drug labeling.
Guideline Update Frequency
PGxAI is designed to adapt quickly to new clinical evidence and emerging biomarkers. The platform continuously learns from real-world evidence to individualize drug therapy. Pharmacogenomic guidelines, such as those from CPIC, are subject to change, and effective infrastructure must be tuned to these updates. The number of medications identified for PGx testing and monitoring continues to increase due to growing research evidence.
Clinical Workflow Integration
PGxAI delivers real-time clinical decision support directly into EHR and hospital workflows, enabling immediate implementation without disrupting existing care processes. It is built on InterSystems IRIS for Health and FHIR-native TrakCare standards, allowing it to ingest longitudinal data directly from EHRs, LIMS, and wearable devices with minimal integration overhead. The platform aims to transform raw genetic data into real-time clinical decision support, providing actionable insights embedded in existing workflows. An update to the PGxAI Andromeda app includes Epic integration for improved connectivity and data exchange.
Decision Audit Trail
PGxAI's platform offers review support and traceability, presenting cited excerpts, source links, and structured review context so clinicians can independently evaluate the basis for each finding. The system maintains an immutable audit log capturing the full decision process, recording every action with a timestamp, including the original user query, patient data elements accessed, unique identifiers of retrieved sources, and the exact steps the reasoning engine took. This audit trail allows clinicians to verify recommendations in real time and review them retrospectively. Regulatory frameworks like FDA 21 CFR Part 11 and EU GMP Annex 11 mandate audit trails for AI-driven decision support tools.
Physician Tip
PGxAI provides evidence-linked pharmacogenomic and medication-safety review, translating complex genetic data into clear clinical guidance. It empowers physicians to proactively adjust dosages or consider safer alternatives, especially for drugs like GLP-1s where genetic variants can increase adverse reaction risks. The platform is designed to integrate seamlessly into existing EHR workflows, offering real-time decision support. Remember that while the tool offers robust guidance, treatment decisions remain with the licensed healthcare professional.
PGxAI has established partnerships with leading technology providers including InterSystems (HealthShare, IRIS for Health, TrakCare), NVIDIA, Google, and Microsoft. It seamlessly integrates with major reporting formats from clinically actionable consumer genetic testing services, allowing users to upload genetic data for actionable insights. Recent updates include improved Epic integration for enhanced connectivity and data exchange.
Details
| Category | Clinical Decision Support & Reference, Pharmacology & Dosing AI |
| Pricing | Contact for pricing |
| Deployment | Cloud-based, EHR integration |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Unknown |
| Integrations | |
| EHR | Not specified |
| Specialties | Family Medicine, Internal Medicine, Oncology |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate PGxAI
Press & Coverage
HIT Consultant
PGxAI Announces Andromeda Precision Prescribing Platform Is Qualified on Mayo Clinic Platform
PGxAI's Andromeda clinical decision-support platform has been qualified on the Mayo Clinic Platform, providing a structured framework for evaluation, validation, integration, and deployment across health systems. The platform unifies pharmacogenomics, multi-omics datasets, and real-world evidence to optimize therapy selection and mitigate adverse drug events.
2026-08
EIN Presswire
PGxAI's Andromeda Outperforms Frontier AI Labs at Clinical Prescribing Guidance
A peer-reviewed study published in npj Digital Medicine demonstrated that PGxAI's Andromeda AI system significantly outperformed large language models like GPT-5, Claude Opus 4, and Grok in generating pharmacogenomic prescribing recommendations. Andromeda is a HIPAA-compliant and SOC 2-compliant platform that integrates various data points for clinician-reviewable guidance.
2026-09
PGxAI
PGxAI and Novo Genomics scale AIu2011enabled pharmacogenomics across Saudi Arabia
PGxAI and Novo Genomics are collaborating to enhance AI-enabled pharmacogenomics in Saudi Arabia, aiming to improve personalized prescribing and medication safety. This initiative includes local lab processing and aligns with Saudi Arabia's Vision 2030 Health Sector Transformation Program.
2026-01
Bis Research
PGxAI and Najashi Holding Collaborate to Revolutionize Precision Medicine in Saudi Arabia
PGxAI has partnered with Najashi Holding to advance precision medicine in Saudi Arabia, integrating AI and genomics into the healthcare infrastructure. This collaboration supports the Kingdom's Vision 2030 to improve patient care and optimize treatment outcomes.
2025-10
FirstWord Pharma
PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Drugs Including Ozempicu00ae
PGxAI released a report detailing an AI-driven genetic tool to personalize treatment with GLP-1 drugs like semaglutide (Ozempic, Wegovy). The report identifies genetic variants influencing drug efficacy and safety, aiming to reduce adverse reactions for patients.
2025-04
PGxAI
PGxAI and Sequencing.com Announce Strategic Partnership to Advance Affordable Pharmacogenomics
PGxAI and Sequencing.com have partnered to make affordable pharmacogenomics accessible at a consumer scale. This collaboration will launch pharmacogenomic reports on Sequencing.com, focusing on reducing adverse drug reactions and enabling safer prescribing.
2025-08
Pharmacogenomics J.
Benchmarking large language models for replication of guideline-based PGx recommendations
A study evaluated large language models (LLMs) for generating clinically accurate pharmacogenomic recommendations aligned with CPIC guidelines. PGxAI Inc. authors contributed to this research, which highlighted the superior performance of domain-adapted models over general-purpose LLMs.
2025-07
PGxAI
PGxAI Launches Sirius, an AIu2011Powered Pharmacogenetics Model, to Advance Ultrau2011Precision Medicine
PGxAI launched Sirius, an AI model that personalizes drug selection, dosage adjustment, and drug-drug interaction management based on an individual's genome. This model aims to enhance clinical efficacy and minimize adverse effects of prescribed therapies.
2024-12
Videos
Product demos, reviews, and walkthroughs for PGxAI.
PGxAI - Sirius AI model (pipeline structure)
PGxAI
PGxAI: Artificial Intelligence Meets the Future of Personalized Medicine
PGxAI
The Future of Personalized Medicine: Betelgeuse PGx and Citalopram
PGxAI
Venture Vitals u2013 Episode IV Mike Zack, PGxAI - an AI-powered pharmacogenetics platform
Digital Health Venture Conversations
Real-Time Tamoxifen Adjustments for Better Patient Outcomes | PGxAI Vega
PGxAI
PGxAI - Refining Recommendations Based on Clinical Outcome Severity
PGxAI
Frequently Asked Questions
PGxAI is designed for seamless integration with most major EHR systems through standard APIs, allowing for direct access to patient genomic data and providing real-time, actionable pharmacogenomic insights at the point of care. This integration minimizes disruption to your current workflow and ensures that PGxAI recommendations are readily available within the patient's chart.
PGxAI's recommendations are based on a comprehensive analysis of peer-reviewed literature, clinical guidelines from organizations like CPIC and PharmGKB, and real-world data. Our algorithms are continuously updated to reflect the latest scientific evidence, and we provide transparent access to the evidence base supporting each recommendation.
PGxAI employs robust security measures, including end-to-end encryption and compliance with HIPAA regulations, to protect patient data. We adhere to strict privacy protocols, ensuring that all genomic and health information is de-identified and anonymized where appropriate, and only accessible to authorized personnel for clinical decision support.
While PGxAI offers valuable insights, it's important to remember that it is a decision support tool and not a substitute for clinical judgment. Limitations may include incomplete genomic data, the influence of non-genomic factors on drug response, and the evolving nature of pharmacogenomic science. Always consider the full clinical picture and individual patient circumstances.
PGxAI offers flexible pricing models tailored to the needs of various practices, ranging from individual clinicians to large hospital systems. Options typically include subscription-based models with different tiers based on the number of users, features accessed, and the volume of pharmacogenomic analyses performed. We can provide a customized quote based on your specific requirements.
Yes, several pharmacogenomic clinical decision support tools exist. PGxAI differentiates itself through its advanced AI-driven algorithms, comprehensive evidence base, seamless EHR integration, and a user-friendly interface designed specifically for clinicians. Our focus is on providing highly actionable and personalized recommendations that are easy to interpret and apply in practice.
PGxAI is regularly updated to incorporate the latest pharmacogenomic guidelines from authoritative bodies and to comply with relevant regulatory requirements. Our system provides clear audit trails for recommendations and can assist in documenting the rationale for prescribing decisions, thereby supporting your compliance efforts.
Suggest an Edit → | Report an issue
| Last Verified: 2026-07-09 | First Added: 2026-07-09